#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adenomatous polyposis coli Iron overload Adenovirus infection Neuroendocrine carcinoma Hepatitis B Systemic candida Hepatic cirrhosis Germ cell cancer Cognitive disorder Encephalitis autoimmune Cerebral amyloid angiopathy Pemphigus Indolent systemic mastocytosis Myxofibrosarcoma Leukoencephalopathy More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia – Basic Information Idiopathic inflammatory myopathy – Diagnostics Methylmalonic acidaemia – Treatment Idiopathic inflammatory myopathy – Life with Disease Focal segmental glomerulosclerosis – Treatment Hereditary optic atrophy – Basic Information Short-bowel syndrome – Trials in Disease Pituitary-dependent Cushing’s syndrome – Basic Information Splenic marginal zone lymphoma Haemophagocytic lymphohistiocytosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    NORGESTIMATE Cellulose, Microcrystalline Modafinil ASP3082 OMECAMTIV MECARBIL Op-1250 Protein C Certolizumab Pegol Tacrolimus Naproxen Sodium CC-97540 Clopidogrel A24110He Bms-986315 Dextromethadone Hydrochloride Corticosteroids, Plain Macitentan Sorafenib Encaleret Sulfate Esomeprazole Magnesium More therapies…

    Learn about Your Condition

    Polycythaemia vera Cutaneous lupus erythematosus Rett syndrome Foot deformity Primary hyperaldosteronism Hepatic angiosarcoma Impaired gastric emptying Melanoma recurrent Liposarcoma Sleep disorder Contusion Psoriasis Acute myocardial infarction Hysterectomy Tonsillitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone receptor positive HER2 negative breast cancer

  • Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Neoplasm malignant
    Investigated Drugs:
    • Fulvestrant
    • Goserelin
    • Leuprorelin Acetate
    Czechia Denmark France Germany Italy Spain

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Cyclophosphamide
    • Docetaxel
    France Germany Italy The Netherlands Spain

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • RLY-2608
    • Capivasertib
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    Investigated Drugs:
    • 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    • Everolimus
    • Exemestane
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    • Breast cancer
    Investigated Drugs:
    • Ribociclib
    Germany

  • Study of elacestrant and exemestane treatment for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer with FES-avid lesions

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Fluoroestradiol F-18
    • Elacestrant
    • Exemestane
    Italy
1 2 3 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!